Maze Therapeutics, Inc. (MAZE)
32.58
+0.13
(+0.40%)
USD |
NASDAQ |
Oct 21, 16:00
32.53
-0.05
(-0.15%)
Pre-Market: 20:00
Maze Therapeutics Net Income (Quarterly) : -44.73M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.73M |
| March 31, 2026 | -24.21M |
| December 31, 2025 | -34.57M |
| September 30, 2025 | -30.09M |
| June 30, 2025 | -33.68M |
| March 31, 2025 | -32.79M |
| Date | Value |
|---|---|
| December 31, 2024 | 10.07M |
| September 30, 2024 | -2.427M |
| March 31, 2024 | -32.49M |
| December 31, 2023 | -26.58M |
| September 30, 2023 | -24.75M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 210.00M |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 44.73M |
| EPS Diluted (Quarterly) | -0.7581 |
| Enterprise Value | 1.458B |
| Earnings Yield | -7.78% |
| Normalized Earnings Yield | -7.786 |